UBE2C is Overexpressed in ESCC Tissues and Its Abrogation Attenuates the Malignant Phenotype of ESCC Cell Lines

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Sep 3

PMID 27588470

Citations 24

Authors

Antonio Palumbo Jr

Nathalia Meireles Da Costa

Marco De Martino

Romina Sepe

Simona Pellecchia

Vanessa Paiva Leite de Sousa

Pedro Nicolau Neto

Cleber Dario Kruel

Anke Bergman

Luiz Eurico Nasciutti

Alfredo Fusco

Luis Felipe Ribeiro Pinto

Affiliations

Soon will be listed here.

Abstract

The esophageal squamous cell carcinoma (ESCC) is widely known as a highly lethal and poor understood cancer, then requiring the search for novel molecular markers to improve its management and patients survival. Recently, ubiquitin-conjugating enzyme E2C (UBE2C) has been figuring as a prominent tumor biomarker candidate, once it has been recognized as a key player in cell cycle progression. In this way, the aim of this study was to evaluate the expression profile of UBE2C gene and protein in ESCC samples, as well as its diagnostic and prognostic marker potential, and its contribution to ESSC genesis and/or progression by performing in vitro functional assays. The analysis of UBE2C gene expression in 52 paired ESCC samples (tumor and respective histologically normal surrounding tissue), by qRT-PCR, revealed that this gene is overexpressed in 73% of ESCC samples. Subsequently, immunohistochemical analysis confirmed that UBE2C protein expression was upregulated in all ESCC cases, but absent in the histologically normal tumor surrounding tissues. Moreover, we showed that UBE2C mRNA expression was able to accurately discriminate ESCC tissue from both healthy esophageal and histologically normal tumor surrounding tissues, pointing out its role as a diagnostic marker for this cancer. Finally, we report that UBE2C affects proliferation rates and cell cycle profile of ESCC cell lines, by directly interfering with cyclin B1 protein levels, suggesting its involvement in crucial steps of ESCC carcinogenesis.

Citing Articles

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus.

Zhu M, Chu Y, Yuan Q, Li J, Chen S, Li L Front Bioinform. 2025; 5:1495052.

PMID: 39944135 PMC: 11810980. DOI: 10.3389/fbinf.2025.1495052.

Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis.

Wu H, Zhu P, Shu P, Zhang S Sci Rep. 2024; 14(1):6894.

PMID: 38519533 PMC: 10959922. DOI: 10.1038/s41598-024-57320-7.

Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance.

Long J, Zhu B, Tian T, Ren L, Tao Y, Zhu H Open Med (Wars). 2023; 18(1):20230757.

PMID: 37840753 PMC: 10571520. DOI: 10.1515/med-2023-0757.

expression is elevated in hepatoblastoma and correlates with inferior patient survival.

Nousiainen R, Eloranta K, Isoaho N, Cairo S, Wilson D, Heikinheimo M Front Genet. 2023; 14:1170940.

PMID: 37377594 PMC: 10291054. DOI: 10.3389/fgene.2023.1170940.

Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma.

He W, Yuan K, He J, Wang C, Peng L, Han Y Ann Transl Med. 2023; 11(2):102.

PMID: 36819552 PMC: 9929830. DOI: 10.21037/atm-22-6512.

References

Chang L, Zhang Z, Yang J, McLaughlin S, Barford D . Atomic structure of the APC/C and its mechanism of protein ubiquitination. Nature. 2015; 522(7557):450-454. PMC: 4608048. DOI: 10.1038/nature14471. View

Mandard A, Hainaut P, Hollstein M . Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000; 462(2-3):335-42. DOI: 10.1016/s1383-5742(00)00019-3. View

Jiang L, Bao Y, Luo C, Hu G, Huang C, Ding X . Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro. J Cancer Res Clin Oncol. 2009; 136(2):211-7. DOI: 10.1007/s00432-009-0651-z. View

Lu J, Wen M, Huang Y, He X, Wang Y, Wu Q . C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics. 2013; 8(6):571-83. PMC: 3857337. DOI: 10.4161/epi.24626. View

Palumbo Jr A, Meireles da Costa N, Bonamino M, Pinto L, Nasciutti L . Genetic instability in the tumor microenvironment: a new look at an old neighbor. Mol Cancer. 2015; 14:145. PMC: 4521350. DOI: 10.1186/s12943-015-0409-y. View

Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y . High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 2013; 13:192. PMC: 3637393. DOI: 10.1186/1471-2407-13-192. View

Townsley F, Aristarkhov A, Beck S, Hershko A, Ruderman J . Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997; 94(6):2362-7. PMC: 20093. DOI: 10.1073/pnas.94.6.2362. View

Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee J . Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009; 2(8):702-11. PMC: 3382104. DOI: 10.1158/1940-6207.CAPR-09-0084. View

Xie C, Powell C, Yao M, Wu J, Dong Q . Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker. Int J Biochem Cell Biol. 2013; 47:113-7. DOI: 10.1016/j.biocel.2013.11.023. View

10.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

11.

Guerriero E, Ferraro A, Desiderio D, Pallante P, Berlingieri M, Iaccarino A . UbcH10 expression on thyroid fine-needle aspirates. Cancer Cytopathol. 2010; 118(3):157-65. DOI: 10.1002/cncy.20046. View

12.

Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J . CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res. 2011; 71(14):4866-76. PMC: 3138908. DOI: 10.1158/0008-5472.CAN-10-4576. View

13.

Pallante P, Malapelle U, Berlingieri M, Bellevicine C, Sepe R, Federico A . UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. Eur J Cancer. 2012; 49(5):1117-26. DOI: 10.1016/j.ejca.2012.09.033. View

14.

Stegmeier F, Rape M, Draviam V, Nalepa G, Sowa M, Ang X . Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature. 2007; 446(7138):876-81. DOI: 10.1038/nature05694. View

15.

Roshandel G, Nourouzi A, Pourshams A, Semnani S, Merat S, Khoshnia M . Endoscopic screening for esophageal squamous cell carcinoma. Arch Iran Med. 2013; 16(6):351-7. DOI: 013166/AIM.009. View

16.

Sivakumar S, Gorbsky G . Spatiotemporal regulation of the anaphase-promoting complex in mitosis. Nat Rev Mol Cell Biol. 2015; 16(2):82-94. PMC: 4386896. DOI: 10.1038/nrm3934. View

17.

Chang L, Barford D . Insights into the anaphase-promoting complex: a molecular machine that regulates mitosis. Curr Opin Struct Biol. 2014; 29:1-9. DOI: 10.1016/j.sbi.2014.08.003. View

18.

Meireles Da Costa N, Lima S, de Almeida Simao T, Pinto L . The potential of molecular markers to improve interventions through the natural history of oesophageal squamous cell carcinoma. Biosci Rep. 2013; 33(4). PMC: 3747595. DOI: 10.1042/BSR20130063. View

19.

Du H, Jie L, Xu W, Wu Y, Liu T, Li M . A monoclonal antibody against a potential cancer biomarker, human ubiquitin-conjugating enzyme E2. Hybridoma (Larchmt). 2012; 31(3):196-202. PMC: 3386004. DOI: 10.1089/hyb.2012.0005. View

20.

Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose M, Gopal G . Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011; 11:80. PMC: 3050856. DOI: 10.1186/1471-2407-11-80. View